Monoclonal antibodies against amyloid beta protein and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10323084
APP PUB NO 20180066044A1
SERIAL NO

15662224

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barghorn, Stefan Mannheim, DE 33 596
Ebert, Ulrich Mannheim, DE 33 642
Hillen, Heinz Hassloch, DE 44 705
Keller, Patrick Darmstadt, DE 36 759
Labkovsky, Boris Wales, US 58 4391
Striebinger, Andreas Speyer, DE 20 251

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 18, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 18, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00